SOURALOVÁ, Tereza, Pavel VENTRUBA, Michal JEŠETA, Daniela ŘEHÁKOVÁ, Aleš HAMPL and Irena KOUTNÁ. Quality control of clinical-grade human embryonic stem cells. In Standardizing Stem Cell Core Facilities in Europe: a CorEuStem Symposium, Lisbon, Portugal. 2023.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Quality control of clinical-grade human embryonic stem cells
Authors SOURALOVÁ, Tereza (203 Czech Republic, belonging to the institution), Pavel VENTRUBA (203 Czech Republic, belonging to the institution), Michal JEŠETA (203 Czech Republic, belonging to the institution), Daniela ŘEHÁKOVÁ (203 Czech Republic, belonging to the institution), Aleš HAMPL (203 Czech Republic, belonging to the institution) and Irena KOUTNÁ (203 Czech Republic, belonging to the institution).
Edition Standardizing Stem Cell Core Facilities in Europe: a CorEuStem Symposium, Lisbon, Portugal, 2023.
Other information
Original language English
Type of outcome Presentations at conferences
Field of Study 10605 Developmental biology
Country of publisher Portugal
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/23:00134631
Organization unit Faculty of Medicine
Keywords in English human embryonic stem cells; quality control
Tags International impact
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 22/4/2024 14:30.
Abstract
Human embryonic stem cells are able to differentiate into every cell type in the human body making them a tremendous cell source for regenerative medicine. However, the production of human embryonic stem cell lines for clinical use is challenging as clean rooms, highly-qualified personnel, and standard operating procedures for both manufacture and quality control are required. Here we present the quality control of clinical-grade hESC lines that were derived in xeno-free, feeder-free conditions, and according to current good manufacturing practices. In-depth quality control provides essential information about the safety, pluripotency, and differentiation potential of lines and it is a necessary component of new clinical-grade hESC line establishment.
Links
CZ.02.1.01/0.0/0.0/16_013/0001826, interní kód MU
(CEP code: EF16_013/0001826)
Name: CZECRIN_PRO PACIENTY - zavádění inovativních moderních terapií
Investor: Ministry of Education, Youth and Sports of the CR, Priority axis 1: Strengthening capacities for high-quality research
NU22-08-00629, research and development projectName: Vývoj postupů pro léčbu makulární degenerace sítnice deriváty lidských pluripotentních kmenových buněk
Investor: Ministry of Health of the CR, Subprogram 1 - standard
PrintDisplayed: 20/7/2024 17:19